Your browser doesn't support javascript.
loading
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
Cai, Lin; Zhang, Jian-Zhong; Yao, Xu; Gu, Jun; Liu, Quan-Zhong; Zheng, Min; Zhang, Shi-Fa; Xu, Jin-Hua; Li, Cheng-Xin; Cheng, Hao; Guo, Qing; Pan, Wei-Li; Li, Shen-Qiu; Li, Ruo-Yu; Guo, Zai-Pei; Song, Zhi-Qi; Li, Shan-Shan; Dong, Xiu-Qin; Wang, Linda; Fu, Rong; Regnault, Pascaline; Charef, Pascal; Mazur, Rafal; Patekar, Manmath.
Afiliación
  • Cai L; Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
  • Zhang JZ; Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
  • Yao X; Institute of Dermatology, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China.
  • Gu J; Department of Dermatology, Changhai Hospital, Shanghai 200433, China.
  • Liu QZ; Department of Dermatology, Tianjin Medical University General Hospital, Tianjin 300052, China.
  • Zheng M; Department of Dermatology, Second Affiliated Hospital School of Medicine, Zhejiang University, Hangzhou, Zhejiang 311215, China.
  • Zhang SF; Department of Dermatology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, China.
  • Xu JH; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
  • Li CX; Department of Dermatology and Venereology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
  • Cheng H; Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.
  • Guo Q; Department of Dermatology, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong 510120, China.
  • Pan WL; Department of Dermatology, Zhejiang Provincial People's Hospital, Zhejiang, Hangzhou, Zhejiang 310014, China.
  • Li SQ; Department of Dermatology, Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei 430030, China.
  • Li RY; Department of Dermatology, Peking University First Hospital, Beijing 100034, China.
  • Guo ZP; Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
  • Song ZQ; Department of Dermatology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China.
  • Li SS; Department of Dermatology, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
  • Dong XQ; Department of Dermatology, Guangdong General Hospital, Guangzhou, Guangdong 510080, China.
  • Wang L; Beijing Novartis Pharma Co. Ltd., Shanghai 201203, China.
  • Fu R; Beijing Novartis Pharma Co. Ltd., Shanghai 201203, China.
  • Regnault P; Novartis Pharma AG, Basel 6463, Switzerland.
  • Charef P; Novartis Pharma AG, Basel 6463, Switzerland.
  • Mazur R; Novartis Pharma AG, Basel 6463, Switzerland.
  • Patekar M; Novartis Pharma AG, Basel 6463, Switzerland.
Chin Med J (Engl) ; 133(22): 2665-2673, 2020 Nov 20.
Article en En | MEDLINE | ID: mdl-33060370
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Chin Med J (Engl) Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Chin Med J (Engl) Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: China